C-0JJPmitochondrial thermogenesis, small-molecule activators, metabolic disorders
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Equator Therapeutics mitochondrial thermogenesis, small-molecule activators, metabolic disorders
Equator Therapeutics is developing pharmacological stimulation of thermogenesis as a treatment approach for obesity and metabolic disorders. The company targets mitochondria and uses high-throughput assays plus direct recording of mitochondrial electrical currents to identify selective activators of thermogenesis. Its long-term plans include programs targeting additional therapeutic mechanisms in mitochondria.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Equator Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic